ADVI in the News

Inflation Reduction Act Federal And State Policy Pharmaceuticals and Biotech

ADVI Health Welcomes Policy Veteran John Coster

Health Policy & Access Strategy Pharmaceuticals and Biotech

Marc Samuels Comments on GLP-1s with Scrip

Cell and Gene Oncology/biologics Pharmaceuticals and Biotech

ADVI and Mix Talent Present: Cell and Gene with Gamida Cell and Zevra Therapeutics

Cell and Gene Oncology/biologics Pharmaceuticals and Biotech

ADVI and Mix Talent Present: Cell and Gene with BridgeBio and Propel Biosciences

Pharmaceuticals and Biotech Pharmaceuticals and Biotech

ADVI Expert Discusses Inflation Reduction Act with Pink Sheet

In this Pink Sheet article, ADVI’s Lindsay Bealor Greenleaf, vice president and head of policy and reimbursement, shares her insights on the first ten drugs on the Medicare negotiation list and some of the factors that went into identifying the drugs.

Advanced Molecular Diagnostics Devices Pharmaceuticals and Biotech Value-Based-Care Federal And State Policy Market Access Pharmaceuticals and Biotech

ADVI Launches ADVI Angle

Pharmaceuticals and Biotech Market Access Pharmaceuticals and Biotech

ADVI Welcomes New Vice President of Market Access

Devices Digital Therapies Pharmaceuticals and Biotech Pharmaceuticals and Biotech

ADVI Welcomes New Head of Business Development Executive

Pharmaceuticals and Biotech Federal And State Policy Pharmaceuticals and Biotech

ADVI Discussed CMS Rx Price Negotiating Staff Transitions with Pink Sheet

Pharmaceuticals and Biotech Federal And State Policy Pharmaceuticals and Biotech

Policy and Reimbursement Director Brenna Raines Discusses CMMI’s New Charge

Pharmaceuticals and Biotech Federal And State Policy Market Access Pharmaceuticals and Biotech

ADVI Leaders Share IRA Insights with Managed Healthcare Executive

"Right now may not be the best time to move forward with the Inflation Reduction Act (IRA) as it could increase inflation through 2024." This was just one key insight that ADVI's Marc Samuels, CEO and president and Lindsay Bealor Greenleaf, vice president and head of policy and reimbursement shared with Managed Healthcare Executive. Read more about what this new law could mean for the healthcare industry and long-term innovation moving forward.

Pharmaceuticals and Biotech Due Diligence Market Access Pharmaceuticals and Biotech

Louis Jacques Discusses New Drug Approvals and Reimbursement with Pink Sheet

ADVI's Louis Jacques, chief clinical officer, sat down with the Pink Sheet to discuss how FDA and CMS are working to ensure a smooth handoff from new drug approval to reimbursement.